RCT Backs SDF for Arresting Severe Early Childhood Caries

A large US randomised clinical trial has found that 38% silver diamine fluoride (SDF) can safely and effectively arrest cavitated dentine carious lesions in young children with severe early childhood caries. Published in JAMA Pediatrics on 27 July 2026, the trial was designed to generate evidence supporting a US FDA approval for SDF in caries arrest, currently used off-label for this indication.

The trial enrolled 830 children under six years with severe early childhood caries across medical, dental and school-based settings, and randomly assigned them to receive either 38% SDF or a placebo at baseline and again after six months. Led by Dr Margherita Fontana at the University of Michigan School of Dentistry, the study reported lesion arrest rates of 50 to 58% in the SDF group compared with 17 to 23% in the placebo group at three, six and eight months. No differences in dental pain were observed, and treatment-related adverse events occurred at similar rates.

SDF has been used internationally since the 1970s to arrest caries, but in the US it is only cleared as a medical device for dentine hypersensitivity in adults, with use for caries arrest remaining off-label. Fontana positioned the study as generating US-population data supporting wider implementation, including in paediatric medical settings where younger children often see paediatricians years before their first dental visit. Co-author Dr Amr M. Moursi at NYU College of Dentistry emphasised that primary care implementation would require appropriate training, protocols and referral pathways. Removing SDF from off-label status could unlock broader utilisation, enhanced insurance payments and more consistent product quality.

The commercial signal is a paediatric dental market on the cusp of significant procedural expansion if the FDA moves SDF to an on-label indication for caries arrest. Elevate Oral Care’s Advantage Arrest, FGM’s Cariestop and other SDF products would benefit from broader utilisation and reimbursement. Expect Elevate Oral Care and Colgate-Palmolive to sharpen their positioning as FDA-approval momentum builds.

For the latest updates and in-depth insights into the world of Animal Health, including breakthrough treatments, industry trends, and regulatory news, contact Albert Baines today!